Dr. Matthew J. Ellis on Neoadjuvant Palbociclib in Primary Breast Cancer

Publication
Video
Special ReportsBreast Cancer (Issue 2)
Volume 1
Issue 2

Matthew J. Ellis, MD, PhD, director, Sue Smith Breast Center at Baylor College of Medicine, discusses a recent study of palbociclib in primary breast cancer.

Matthew J. Ellis, MD, PhD, director, Sue Smith Breast Center at Baylor College of Medicine, discusses a recent study of palbociclib in primary breast cancer. Ellis says while all the data on palbociclib prior to this study was in metastatic disease, this study looked at the treatment in the neoadjuvant setting for patient with breast cancer.

Related Videos
Video 3 - "Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies"
Video 2 - "EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection"
Video 1 - "A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection"
Rohit Gosain, MD; Rahul Gosain, MD; and Hope Rugo, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Hope Rugo, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Hope Rugo, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Hope Rugo, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Hope Rugo, MD, presenting slides
Related Content